BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33037428)

  • 1. Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
    Kobayashi Y; Hirasawa A; Chiyoda T; Ueki A; Masuda K; Misu K; Kawaida M; Hayashi S; Kataoka F; Banno K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):213-217. PubMed ID: 33037428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
    Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
    Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
    Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience.
    Nagashima M; Ishikawa T; Asami Y; Hirose Y; Shimada K; Miyagami S; Mimura T; Miyamoto S; Onuki M; Morioka M; Izumi M; Yoshida R; Yamochi T; Taruno K; Nakamura S; Sekizawa A; Matsumoto K
    Jpn J Clin Oncol; 2023 Jun; 53(6):472-479. PubMed ID: 36999211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline
    Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M
    Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
    Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
    Nomura H; Sekine M; Yokoyama S; Arai M; Enomoto T; Takeshima N; Nakamura S
    Int J Clin Oncol; 2019 Sep; 24(9):1105-1110. PubMed ID: 31055694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    Carr CE; Chambers L; Jernigan AM; Freeman L; Escobar PF; Michener CM
    Int J Gynecol Cancer; 2021 Feb; 31(2):215-221. PubMed ID: 32948638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
    Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
    Hirasawa A; Masuda K; Akahane T; Ueki A; Yokota M; Tsuruta T; Nomura H; Kataoka F; Tominaga E; Banno K; Makita K; Susumu N; Sugano K; Kosaki K; Kameyama K; Aoki D
    Jpn J Clin Oncol; 2014 Jan; 44(1):49-56. PubMed ID: 24218521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.